You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Express Scripts
Colorcon
Johnson and Johnson
Dow
Baxter
Medtronic

Last Updated: September 22, 2020

DrugPatentWatch Database Preview

Patent: 9,315,826

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,315,826
Title:Nucleic acids containing a synthetic codon-optimized Sin Nombre virus full-length M gene
Abstract: The invention contemplates a new synthetic, codon-optimized Sin Nombre virus (SNV) full-length M gene open reading frame (ORF) that encodes a unique consensus amino acid sequence. The SNV ORF was cloned into a plasmid to form the first stable recombinant SNV full-length M gene that elicits neutralizing antibodies. The gene can be engineered into a vaccine system, and is useful to protect mammals against infection with Sin Nombre virus.
Inventor(s): Hooper; Jay (New Market, MD)
Assignee: The United States of America as rep. by the Sec\'y of the Army, for U.S. Army Medical Research Institute of Infectious Diseases (Washington, DC)
Application Number:13/982,606
Patent Claims:see list of patent claims

Details for Patent 9,315,826

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04   Start Trial The United States of America as rep. by the Sec\'y of the Army, for U.S. Army Medical Research Institute of Infectious Diseases (Washington, DC) 2039-02-26 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04   Start Trial The United States of America as rep. by the Sec\'y of the Army, for U.S. Army Medical Research Institute of Infectious Diseases (Washington, DC) 2039-02-26 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04   Start Trial The United States of America as rep. by the Sec\'y of the Army, for U.S. Army Medical Research Institute of Infectious Diseases (Washington, DC) 2039-02-26 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Medtronic
Express Scripts
Boehringer Ingelheim
Colorcon
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.